Text Size

A Study of MK0777 in the Treatment of Outpatients With Generalized Anxiety Disorder

This study has been completed.
Sponsor:
Information provided by:
Merck
ClinicalTrials.gov Identifier:
NCT00543920
First received: October 5, 2007
Last updated: October 12, 2007
Last verified: October 2007
History of Changes
  Purpose

The study will look at the effect of MK0777on reducing anxiety in subjects with general anxiety disorder.

This is an early phase trial and some specific protocol information is in progress and not publicly available at this time. (Full information is available to trial participants).


Condition Intervention Phase
Anxiety Disorders
 Drug: MK0777
 Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment

Resource links provided by NLM:

MedlinePlus related topics: Anxiety
U.S. FDA Resources

Further study details as provided by Merck:

Study Start Date: October 2002
Study Completion Date: September 2003
  Eligibility

Ages Eligible for Study:   18 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diagnosis of General Anxiety Order

Exclusion Criteria:

  • Women who are pregnant or breast-feeding
  • History of severe drug reaction
  • History of severe drug withdrawal symptoms such as seizures or delirium
  • Disease of cardiovascular system
  • Disease of the liver, kidneys, endocrine system, metabolic system or eyes
  • History of seizures or seizure disorder
  • History of drug or alcohol abuse
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00543920

Sponsors and Collaborators
Merck
Investigators
Study Director: Medical Monitor Merck
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00543920     History of Changes
Other Study ID Numbers: 2007_633
Study First Received: October 5, 2007
Last Updated: October 12, 2007
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Anxiety Disorders
Mental Disorders

ClinicalTrials.gov processed this record on May 23, 2013